0001178913-23-002732.txt : 20230808 0001178913-23-002732.hdr.sgml : 20230808 20230808060050 ACCESSION NUMBER: 0001178913-23-002732 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230808 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 231149152 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 6-K 1 zk2330126.htm 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2023
 
Commission File Number 001-38807
 
CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)
 
Kiryat Atidim, Building 7, Tel-Aviv, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F ☒           Form 40-F ☐
 
 
 
EXPLANATORY NOTE
 
Chemomab Therapeutics Ltd. (the “Company”) today announced the results of its annual general shareholders meeting (the “Meeting”), which was held on August 7, 2023 at 4:30 p.m. (Israel time), at Meitar | Law Offices, located at 16 Abba Hillel Road, 10th floor, Ramat Gan 5250608, Israel.

At the Meeting, the Company’s shareholders voted upon and approved, by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, the following proposals: (i) the re-election of each of Dr. Claude Nicaise and Mr. Neil Cohen as Class II directors, (ii) the amendment of the compensation terms of the Company’s chief executive officer, Dr. Adi Mor, (iii) the amendment of the compensation terms of the non-executive members of the Board of Directors of the Company, and (iv) the approval of the re-appointment of Somekh Chaikin, a member firm of KPMG international, as the Company’s independent registered public accounting firm; all in accordance with the Company’s proxy statement related to the Meeting, which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K furnished to the Securities and Exchange Commission on July 3, 2023.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-3 (File No. 333-255658) and Form S-8 (File No. 333-259489, and No. 333-266868).

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
CHEMOMAB THERAPEUTICS LTD.
 
 
 
Date: August 8, 2023
By:
/s/ Sigal Fattal
 
 
Sigal Fattal
 
 
Chief Financial Officer